The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer

Starting soon · Phase 3

Conditions studied: Advanced Bladder Cancer

In brief

The goal of this clinical trial is to learn if the timing of treatments plays a role in how effective the standard-of-care drugs enfortumab vedotin and pembrolizumab (EV/P) works to treat adults with advanced bladder cancer. The trial will also learn if time-of-day reduces EV/P side-effects. Researchers will compare EV/P given in the morning (before 11:30am) vs in the afternoon (after 1:30pm), to see if circadian rhythm effects how EV/P works to treat advanced bladder cancer. Participants will be randomized in Arm A or Arm B to receive drugs EV/P either in the morning (Arm A) or afternoon (Arm B) as part of their standard-of-care treatment for advanced bladder cancer. Participants will: * Visit the clinic either in the morning (Arm A) or afternoon (Arm B) to receive EV/P treatment as part of their regular medical care for advanced bladder cancer * Frequency of visits will follow standard-of-care guidelines * Participants will be followed-up by the study team for up to 24 months.

Key facts

Study ID

NCT07346053

Run by

Guliz Ozgun

People needed

224

Starts

2026-05-01

Expected to finish

2032-12-01

Last updated by the study team

2026-01-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must meet all of the following inclusion criteria to be eligible for participation in this trial:
• Age 18 or older
• Able to provide informed consent
• Histologically confirmed advanced urothelial cancer
• Eligible for standard-of-care EV/P regimen
• Measurable disease per RECIST 1.1
• ECOG performance status 0-2
• Ability to adhere to scheduled infusion times (Before 11:30 a.m. or after 1:30 pm) Waivers to the inclusion criteria will NOT be allowed.

You may not qualify if…

• Participants who meet any of following exclusion criteria will not be eligible for participation in this trial:
• Non-urothelial histology or mixed histology with predominant non-urothelial components
• Concurrent malignancy requiring active systemic therapy, unless disease-free for at least 2 years
• Inability to comply with protocol-specified infusion timing for at least the first 3 months
• Night shift workers
• Clinical evidence of new or enlarging brain metastasis or carcinomatous meningitis
• Known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial
• Patients who have traveled across ≥2 time zones within the past 14 days prior to randomization will be excluded, due to potential disruption of circadian rhythms (jet lag), which may affect chronotherapy-related endpoints.
• Patients with a clinically diagnosed sleep disorder, including but not limited to insomnia, obstructive sleep apnea, restless leg syndrome, or circadian rhythm sleep-wake disorders, that is moderate to severe, untreated, or poorly controlled, will be excluded.
• Waivers to the exclusion criteria will NOT be allowed.

Where it is running

• BC Cancer - Abbotsford — Abbotsford British Columbia, British Columbia, Canada
• BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre) — Kelowna, British Columbia, Canada
• BC Cancer - Surrey — Surrey, British Columbia, Canada
• BC Cancer - Vancouver Cancer Centre — Vancouver, British Columbia, Canada
• BC Cancer - Victoria — Victoria, British Columbia, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.